Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ciclesonide
Drug ID BADD_D00460
Description Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indications and Usage For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Marketing Status approved; investigational
ATC Code R01AD13; R03BA08
DrugBank ID DB01410
KEGG ID D01703
MeSH ID C120481
PubChem ID 6918155
TTD Drug ID D0K7HU
NDC Product Code 70515-711; 53104-7633; 70515-712; 70515-701; 64918-1900; 24002-0016; 64918-1112; 70515-737
UNII S59502J185
Synonyms ciclesonide | (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | Alvesco | Omnaris
Chemical Information
Molecular Formula C32H44O7
CAS Registry Number 126544-47-6
SMILES CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Contusion23.03.11.002; 12.01.06.001; 15.03.05.007; 24.07.06.001--
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Rhinalgia22.12.03.020--Not Available
Nasal discomfort22.12.03.012--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling08.02.03.017; 12.07.03.018--Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Haemorrhage24.07.01.002--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Mediastinal disorder22.09.03.001--Not Available
Oral fungal infection11.03.05.010; 07.05.07.009--Not Available
Obstructive airways disorder22.03.01.011--Not Available
Unevaluable event08.01.03.0510.001288%Not Available
Treatment failure08.06.01.017--Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.0160.000834%
Candida infection11.03.03.021--
Sensitivity to weather change08.01.03.077--Not Available
Illness08.01.03.091--Not Available
Sleep disorder due to a general medical condition19.02.04.0030.000947%Not Available
Therapeutic product effect decreased08.06.01.050--Not Available
Therapeutic product effect incomplete08.06.01.0520.000568%Not Available
The 6th Page    First    Pre   6    Total 6 Pages